Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05040568 · ClinicalTrials.gov registry record · Phase 1
A Phase IB Study OF Immunotherapy With EX Vivo Pre-activated AND Expanded Cb-nk Cells IN Combination With Cetuximab, IN Colorectal Cancer Patients With Minimal Residual Disease (MRD)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05040568: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT05040568 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05040568, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine phosphate
- DRUG Cetuximab
- DRUG Expanded CB-NK cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-02-28 |
| Est. Completion | 2026-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05040568
The ClinicalTrials.gov registry entry for NCT05040568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT05040568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05040568 about?
NCT05040568 is a clinical study titled "A Phase IB Study OF Immunotherapy With EX Vivo Pre-activated AND Expanded Cb-nk Cells IN Combination With Cetuximab, IN Colorectal Cancer Patients With Minimal Residual Disease (MRD)". A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA
What is the current status of trial NCT05040568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-02-28. Estimated completion is 2026-01-15.
What interventions are being tested in trial NCT05040568?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine phosphate (DRUG), Cetuximab (DRUG), Expanded CB-NK cells (DRUG).
Who is sponsoring clinical trial NCT05040568?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.